Cannara Biotech Statistics

Total Valuation

Cannara Biotech has a market cap or net worth of CAD 160.37 million. The enterprise value is 187.59 million.

Market Cap	160.37M
Enterprise Value	187.59M

Important Dates

The next estimated earnings date is Monday, January 26, 2026.

Earnings Date	Jan 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Cannara Biotech has 94.90 million shares outstanding. The number of shares has increased by 1.08% in one year.

Current Share Class	94.90M
Shares Outstanding	94.90M
Shares Change (YoY)	+1.08%
Shares Change (QoQ)	+0.83%
Owned by Insiders (%)	2.20%
Owned by Institutions (%)	0.23%
Float	44.76M

Valuation Ratios

The trailing PE ratio is 12.07 and the forward PE ratio is 9.94.

PE Ratio	12.07
Forward PE	9.94
PS Ratio	1.50
PB Ratio	1.57
P/TBV Ratio	1.57
P/FCF Ratio	11.74
P/OCF Ratio	8.01
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.62, with an EV/FCF ratio of 13.74.

EV / Earnings	14.35
EV / Sales	1.75
EV / EBITDA	6.62
EV / EBIT	8.66
EV / FCF	13.74

Financial Position

The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.41.

Current Ratio	2.40
Quick Ratio	0.83
Debt / Equity	0.41
Debt / EBITDA	1.47
Debt / FCF	3.05
Interest Coverage	5.75

Financial Efficiency

Return on equity (ROE) is 13.75% and return on invested capital (ROIC) is 9.67%.

Return on Equity (ROE)	13.75%
Return on Assets (ROA)	8.37%
Return on Invested Capital (ROIC)	9.67%
Return on Capital Employed (ROCE)	16.11%
Revenue Per Employee	237,174
Profits Per Employee	28,930
Employee Count	452
Asset Turnover	0.66
Inventory Turnover	1.32

Taxes

In the past 12 months, Cannara Biotech has paid 5.02 million in taxes.

Income Tax	5.02M
Effective Tax Rate	27.74%

Stock Price Statistics

The stock price has increased by +119.48% in the last 52 weeks. The beta is 0.32, so Cannara Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.32
52-Week Price Change	+119.48%
50-Day Moving Average	1.71
200-Day Moving Average	1.55
Relative Strength Index (RSI)	50.19
Average Volume (20 Days)	60,485

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cannara Biotech had revenue of CAD 107.20 million and earned 13.08 million in profits. Earnings per share was 0.14.

Revenue	107.20M
Gross Profit	47.10M
Operating Income	21.66M
Pretax Income	18.10M
Net Income	13.08M
EBITDA	28.06M
EBIT	21.66M
Earnings Per Share (EPS)	0.14

Full Income Statement

Balance Sheet

The company has 14.36 million in cash and 41.58 million in debt, giving a net cash position of -27.22 million or -0.29 per share.

Cash & Cash Equivalents	14.36M
Total Debt	41.58M
Net Cash	-27.22M
Net Cash Per Share	-0.29
Equity (Book Value)	102.22M
Book Value Per Share	1.12
Working Capital	47.96M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 20.01 million and capital expenditures -6.36 million, giving a free cash flow of 13.65 million.

Operating Cash Flow	20.01M
Capital Expenditures	-6.36M
Free Cash Flow	13.65M
FCF Per Share	0.14

Full Cash Flow Statement

Margins

Gross margin is 43.94%, with operating and profit margins of 20.20% and 12.20%.

Gross Margin	43.94%
Operating Margin	20.20%
Pretax Margin	16.88%
Profit Margin	12.20%
EBITDA Margin	26.18%
EBIT Margin	20.20%
FCF Margin	12.74%

Dividends & Yields

Cannara Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.08%
Shareholder Yield	-1.08%
Earnings Yield	8.15%
FCF Yield	8.51%

Stock Splits

The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Feb 13, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Cannara Biotech has an Altman Z-Score of 2.35 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.35
Piotroski F-Score	7